SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Overspending driven by oversized single dose vials of cancer drugs
0 references·7 citing·21 second hop
Overspending driven by oversized single dose vials of cancer drugs (2016)Overspending driven by oversized single d…Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000–20: a retrospective analysis (2024)Population-health impact of n…What cancer research makes the news? A quantitative analysis of online news stories that mention cancer studies (2021)What cancer research makes th…Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments (2021)Near-Equivalence: Generating …Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value (2020)Interventional Pharmacoeconom…Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma (2018)Cost-Effectiveness Analysis o…Making individualized drugs a reality (2017)Making individualized drugs a…A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non–Small Cell Lung Cancer (2017)A Phamacoeconomic Analysis of…Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force (2013)Indication-Specific Pricing for Cancer Drugs (2014)Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US (2020)Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group (2012)Towards a sustainable system of drug development (2014)We Cannot Win the Access to Medicines Struggle Using the Same Thinking That Causes the Chronic Access Crisis. (2021)Recommendations of the Panel on Cost-Effectiveness in Health and Medicine (1996)Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves (2012)Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold (2014)Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011 (2015)Bringing down the cost of cancer treatment (2018)Interventional Pharmacoeconomics—A New Discipline for a Cost-Constrained Environment (2019)Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial (2016)Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial (2016)Beyond journalism: Theorizing the transformation of journalism (2017)Making science public: a review of journalists’ use of Open Access research (2024)Second-order citations in altmetrics: A case study analyzing the audiences of COVID-19 research in the news and on social media (2024)The many publics of science: using altmetrics to identify common communication channels by scientific field (2024)Net Health Benefits (1998)Methods for the Economic Evaluation of Health Care Programmes (2005)The NICE Cost-Effectiveness Threshold (2008)
this work references cited by second hop

References

No references inside the corpus for this window.

Cited by

  • 2017A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non–Small Cell Lung Cancer106 cited
  • 2024Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000–20: a retrospective analysis85 cited
  • 2020Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value55 cited
  • 2021Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments54 cited
  • 2017Making individualized drugs a reality50 cited
  • 2018Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma50 cited
  • 2021What cancer research makes the news? A quantitative analysis of online news stories that mention cancer studies16 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work